

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



July 01, 2021

National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Sub: Press Release

Dear Sir / Madam,

Please find enclosed herewith our Press Release relating to the launch of 'Sunkalp' on the occasion of National Doctors' Day, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

Ashok I. Bhuta
Compliance Officer
Enclosed: As above

FOR IMMEDIATE RELEASE

Sun Pharma launches 'Sunkalp' on the occasion of National Doctors' Day

As a special tribute, announces various initiatives for the welfare of doctors, their families and the community

Mumbai, India, July 1, 2021: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced the launch of a special initiative 'Sunkalp' for the welfare of doctors, their families and the community.

Doctors have been working relentlessly through the pandemic putting their lives at risk to safeguard society. To recognise and care for their health & well-being, on the occasion of National Doctors' Day, Sun Pharma announces the launch of multifaceted initiatives under Sunkalp. These initiatives will be rolled out in a phased manner.

- Mental health support for doctors & their families
- Webinars for doctors on mental health by experts
- Donation of Covid-19 medicines (phase 2)
- Post Doctorate educational sponsorship (phase 2)
- Educational aid for children of doctors who lost their lives to Covid-19 (phase 2)

Sun Pharma has committed Rs. 100 crores towards these initiatives, which includes donation of Covid-19 medicines to communities at large through local & state government institutions.

For more than a year, doctors have been fighting the pandemic to save lives. Long stressful working hours, witnessing casualties and maintaining distance from loved ones have become normal for them. These factors can result in stress & exhaustion not only for them but also for their families. To help them cope with the same, Sun Pharma has partnered with [Mann Talks](#) to provide doctors and their families with **confidential emotional and psychological care** by trained mental health professionals. Further, to educate doctors on mental health issues & enable them to take better self-care, multiple **webinars** will be held by experts.

Kirti Ganorkar, CEO – India Business, Sun Pharma, said, "Indian healthcare professionals have faced unprecedented challenges during the pandemic, and their determination to fight against all odds inspires us every day. Sunkalp is a tribute to these heroes for their selfless acts of sacrifice and kindness. Through this initiative, we want to extend our gratitude to them and contribute to strengthening the healthcare ecosystem."

The pandemic outbreak has affirmed the need for more medical research to meet unforeseen situations. To encourage research, Sun Pharma will sponsor postgraduate medical students for medical

Sun Pharmaceutical Industries Limited.

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



& clinical research in various fields. More than 1000 young scholars will receive **grants** for their research projects.

To pay homage to doctors who have lost their lives to Covid-19, Sun Pharma is setting up an **Education Fund** for their children. The company will provide educational grants to the affected families through this fund.

Sun Pharma has launched a website, <https://sunpharmasunkalp.com/> that gives more details on the initiatives under Sunkalp.

The Sunkalp initiative is restricted to India.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

Contacts:

Investors:

Nimish Desai
Tel +91 22 4324 4324, Xtn 2778
Tel Direct +91 22 4324 2778
Mobile +91-98203 30182
E mail nimish.desai@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com